Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mosaic HIV-1 envelope trimer immunogens + monophosphoryl lipid A liposomes
- Development stage
- Unknown
- Lead developer
- Polymun Scientific
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Mosaic HIV-1 envelope trimer immunogens (MOS1SIP, MOS2SIP, M3SIP8) combined with the adjuvant monophosphoryl lipid A liposomes (MPLA-5) is an investigational therapeutic vaccine regimen primarily focused on preventive HIV vaccine development. The approach uses engineered "mosaic" envelope proteins designed to elicit broad immune responses against diverse global strains of HIV. The MPLA-5 component acts as an adjuvant to enhance the immune response. This combination is being evaluated in clinical trials for its ability to induce neutralizing antibodies and potentially assist in both prevention and cure research for HIV infection[2][6][7].
- Other names
- HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes
02
Targets
Env (HIV-1 envelope glycoprotein)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on mosaic HIV-1 envelope trimer immunogens + monophosphoryl lipid A liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mosaic HIV-1 envelope trimer immunogens + monophosphoryl lipid A liposomes.